Skip to Content
Biotechnology and health

Billions of dollars are at stake, so the fight over who owns CRISPR is back in court

April 30, 2018

Credit for a game-changing breakthrough in biotechnology, a potential Nobel Prize, and oh yes, gobs of money have proved motive enough for the University of California, Berkeley, to keep up its all-but-lost dispute with the Broad Institute of MIT and Harvard over who owns the rights to the gene-editing tool CRISPR. The two parties squared off again today in a federal court in Washington, DC.

Background: The Berkeley team and its collaborators first filed a patent application in May 2012 for the basic CRISPR technology. In December of that year, Broad researchers filed an application but paid an extra fee for an expedited route to patent CRISPR in eukaryotic cells—those in plants, animals, and people. The Broad was granted several patents.

Patent fight: Berkeley challenged that decision, asking the US Patent & Trademark Office to reconsider. In a ruling last year, the office’s patent trial and appeal board decided in favor of the Broad, saying the two teams’ discoveries didn’t overlap and that the Broad’s patents covered a truly separate innovation.

Appeal: The University of California appealed that decision, and today it tried to convince federal judges in DC that the patent board made legal errors when it issued its ruling. The judges didn’t seem swayed—but they won’t issue a written decision until later this year at the earliest.

CRISPR’s future: At stake is potentially billions of dollars in licensing agreements. If the Broad ultimately prevails, companies currently licensing technology from the University of California—like CRISPR Therapeutics and Intellia Therapeutics—will instead need to seek approval from the Broad Institute for rights to use CRISPR. That could send their stock tumbling and possibly delay their plans to begin clinical trials using the gene-editing technology.

Deep Dive

Biotechnology and health

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Some deaf children in China can hear after gene therapy treatment

After deafness treatment, Yiyi can hear her mother and dance to the music. But why is it so noisy at night?

Scientists just drafted an incredibly detailed map of the human brain

A massive suite of papers offers a high-res view of the human and non-human primate brain.

Three people were gene-edited in an effort to cure their HIV. The result is unknown.

CRISPR is being used in an experimental effort to eliminate the virus that causes AIDS.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.